Ragweed is an allergen for people allergic to ragweed. Ragweed pollen is made of tiny particles that float through the air and cause allergy symptoms in people who are allergic to ragweed. Of all ragweed allergy symptoms, cough, runny nose, and an itchy throat are the most common. Ragweed pollen is a powdery substance that consists of tiny particles, or grains. The grains of pollen help fertilize other ragweed plants. One ragweed plant can produce up to 1 billion pollen grains that can float through the air, and either produce seeds or end up in the nose, eyes or mouth, causing great discomfort if a person is allergic to it. Pollen can also collect on clothes, hair, and the skin. Like all pollen allergies, allergies to ragweed can lead to seasonal allergic rhinitis (hay fever), inflammation of the nasal passages. For people with a ragweed allergy, exposure to the plant by touch or through airborne particles can lead to them developing a ragweed rash. Other common ragweed allergy symptoms are: nasal congestion, runny nose with thin, water discharge, postnasal drip, sneezing, coughing, watery, itchy or irritated eyes, eye swelling– the “allergic shiner”, weakness or fatigue, hives on the skin. A person who has been exposed to ragweed pollen may notice itchy red streaks appearing on his skin 24 to 48 hours after exposure. The rash can be painful and may form into blisters. Ragweed rash can last anywhere from two to three weeks and will usually improve on its own. Ragweed pollen can cause asthma symptoms to flare up. When a person with asthma and ragweed allergy inhales ragweed pollen, it can cause the lungs and airways to become inflamed and swollen. People with allergic asthma will require treatment for its asthma symptoms, but they may also require treatment for its allergies.
Increasing launches of new products, and mergers and acquisitions by key market players is expected to drive the global ragweed pollen allergy treatment market growth. For instance, on April 19, 2021, ALK, a Denmark-based pharmaceutical company which specializes in the development and manufacture of allergy immunotherapy (AIT) products for the prevention and treatment of allergy, announced that the U.S. Food and Drug Administration (FDA) approved RAGWITEK (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use for the treatment of short ragweed pollen-induced allergic rhinitis in persons ages five through 65. RAGWITEK is an allergen extract indicated as immunotherapy for the treatment of short ragweed pollen-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen.
Key features of the study:
Table of Contents
*Browse 32 market data tables and 27 figures on “Ragweed Pollen Allergy Treatment Market”- Global forecast to 2030